Fortrea Holdings Inc. (FTRE)
NASDAQ:FTRE
Want to see FTRE full AI Analyst Report?
Top Page
Fortrea Holdings Inc.
(NASDAQ:FTRE)
Select Model
Select Model
Rating:55Neutral
Price Target:
$12.50
▲(20.42% Upside)
Action:ReiteratedDate:05/05/26
The score is held back primarily by weak recent profitability and a negative P/E, despite meaningful debt reduction and still-positive (but weakening) free cash flow. Technicals add support with positive trend and momentum, though near-overbought signals raise near-term risk. The latest earnings call improves the outlook modestly via reiterated guidance, improving book-to-bill/backlog and cost savings progress, but near-term revenue pressure and cash-flow negativity remain important constraints.
Positive Factors
Backlog & Book-to-Bill
A $7.8B backlog and book-to-bill above 1 provide durable revenue visibility and pipeline conversion potential. Sustained backlog supports multi-quarter revenue coverage, smoothing the business cycle and enabling predictable resource planning and capacity investments.
Negative Factors
Profitability Deterioration
Sustained and large net losses undermine return generation and equity value, constrain reinvestment, and limit ability to self-fund growth. Turning sizable negative margins into consistent profitability will require persistent commercial and structural cost progress over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Backlog & Book-to-Bill
A $7.8B backlog and book-to-bill above 1 provide durable revenue visibility and pipeline conversion potential. Sustained backlog supports multi-quarter revenue coverage, smoothing the business cycle and enabling predictable resource planning and capacity investments.
Read all positive factors
Fortrea Holdings Inc. (FTRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.48B
Dividend YieldN/A
Average Volume (3M)1.80M
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue Growth0.86%
EPS Growth42.65%
CountryUS
Employees15,000
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.97
Shares Outstanding93,500,000
10 Day Avg. Volume2,205,510
30 Day Avg. Volume1,801,545
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.58
P/FCF Ratio17.82
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit3.12
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$15.38Price Target Upside48.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.71
Revenue Forecast (FY)$2.59B
Fortrea Holdings Inc. Business Overview & Revenue Model
Company Description
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. ...
How the Company Makes Money
Fortrea makes money primarily by delivering outsourced clinical development services to life sciences customers under contracted arrangements. Revenue is generated through service contracts tied to specific clinical development programs (e.g., run...
Fortrea Holdings Inc. Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The call balanced clear operational and commercial progress (book-to-bill >1.1x, adjusted EBITDA growth, large backlog, strong cost savings, FIT launch, China momentum and improved cash flow metrics) against near-term revenue pressure driven by lower pass-throughs and FSP pricing concessions, customer concentration and continued negative (though improved) Q1 cash flow. Management reiterated full-year guidance and a multi-year plan to reach mid-teens adjusted EBITDA margins. Overall, the positive operational, financial and commercial momentum and materially improved profitability and cash metrics outweigh the listed headwinds.Positive Updates
Improved Commercial Traction - Book-to-Bill Above 1
Q1 book-to-bill of 1.15x and trailing 12-month book-to-bill of 1.05x, marking the third consecutive quarter with book-to-bill >= 1.1x and indicating improving sales execution and pipeline momentum (notably new-to-Fortrea biotech wins).
Negative Updates
Year-over-Year Revenue Decline
Q1 revenue declined 2.3% YoY (to $636.5M), including a 3.2% constant currency decline partially offset by a 0.9% currency benefit; decline driven primarily by lower pass-through costs and continued FSP headwinds.
Read all updates
Q1-2026 Updates
Positive
Negative
Improved Commercial Traction - Book-to-Bill Above 1
Q1 book-to-bill of 1.15x and trailing 12-month book-to-bill of 1.05x, marking the third consecutive quarter with book-to-bill >= 1.1x and indicating improving sales execution and pipeline momentum (notably new-to-Fortrea biotech wins).
Read all positive updates
Company Guidance
Fortrea reiterated full‑year 2026 guidance of $2.55–2.65 billion in revenue and $190–220 million in adjusted EBITDA while targeting mid‑teens adjusted EBITDA margins over the next 3–5 years; management expects a modest sequential revenue increase in Q2 and a slight step‑up in adjusted EBITDA (partly offset by higher variable compensation). Q1 underpinned the outlook with revenue of $636.5M, adjusted EBITDA $47M, book‑to‑bill 1.15x (TTM 1.05x), backlog $7.8B and backlog burn 8.2%; Q1 results also included net loss $23.6M, adjusted net income $15.2M (adj. EPS $0.16), operating cash flow −$17M and free cash flow −$25M, DSO 20 days and net A/R & unbilled $619.6M. Management reported nearly $16M of gross and >$9M of net quarterly cost savings toward full‑year targets of $70–80M gross / $40–50M net, reiterated plans to be operating cash‑flow positive in the remainder of 2026, noted available liquidity in excess of $0.5B, and highlighted ~35% of original debt repaid since the spin.Fortrea Holdings Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
54
Neutral
Cash Flow
43
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.72B | 2.70B | 2.84B | 2.84B | 3.06B |
| Gross Profit | 425.80M | 534.20M | 590.60M | 724.40M | 604.40M |
| EBITDA | -813.60M | -64.30M | 137.20M | 280.80M | 302.90M |
| Net Income | -986.20M | -328.50M | -25.20M | 186.20M | 98.00M |
Balance Sheet | |||||
| Total Assets | 2.72B | 3.58B | 4.33B | 4.29B | 4.37B |
| Cash, Cash Equivalents and Short-Term Investments | 174.60M | 118.50M | 108.60M | 112.00M | 94.60M |
| Total Debt | 68.00M | 1.20B | 1.67B | 63.40M | 77.20M |
| Total Liabilities | 2.15B | 2.22B | 2.62B | 945.30M | 1.11B |
| Stockholders Equity | 563.50M | 1.36B | 1.71B | 3.34B | 3.26B |
Cash Flow | |||||
| Free Cash Flow | 88.30M | 237.30M | 128.10M | 28.30M | 143.30M |
| Operating Cash Flow | 113.50M | 262.80M | 168.40M | 82.70M | 169.80M |
| Investing Cash Flow | 14.40M | 251.60M | -31.80M | -54.00M | -26.20M |
| Financing Cash Flow | -76.30M | -497.80M | -140.80M | -6.30M | -128.50M |
Fortrea Holdings Inc. Technical Analysis
Neutral
10.38
Price Trends
10.20
Positive
13.09
Negative
10.87
Negative
Market Momentum
-0.11
Negative
57.14
Neutral
81.76
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FTRE, the sentiment is Neutral. The current price of 10.38 is above the 20-day moving average (MA) of 9.52, above the 50-day MA of 10.20, and below the 200-day MA of 10.87, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 57.14 is Neutral, neither overbought nor oversold. The STOCH value of 81.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FTRE.
Fortrea Holdings Inc. Risk Analysis
Fortrea Holdings Inc. disclosed 57 risk factors in its most recent earnings report. Fortrea Holdings Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Fortrea Holdings Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $2.83B | -5.95 | -399.10% | ― | -43.89% | -17.07% | |
56 Neutral | $532.22M | -3.22 | -71.25% | ― | ― | -3.52% | |
55 Neutral | $1.48B | ― | -79.12% | ― | 0.86% | 42.65% | |
55 Neutral | $473.76M | -7.74 | -27.80% | ― | -100.00% | -2365.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $336.76M | -13.46 | -39.75% | ― | -100.00% | -2.72% | |
45 Neutral | $3.39B | -9.06 | -34.48% | ― | ― | 41.14% |
* Healthcare Sector Average
FTRE
Fortrea Holdings Inc.
15.64
10.01
177.80%
NKTR
Nektar Therapeutics
85.09
76.01
836.70%
FULC
Fulcrum Therapeutics
7.11
2.04
40.24%
CMPX
Compass Therapeutics
1.87
0.11
6.25%
ERAS
Erasca
10.90
9.68
793.44%
AURA
Aura Biosciences Inc
8.29
3.32
66.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.